Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists

Gracen, Lucy; Muthukumara, Withma; Aikebuse, Melanie; Russell, Anthony; Irvine, Katharine M.; Williams, Suzanne T.; Puri, Gaurav; Valery, Patricia C.; Hayward, Kelly L.; Powell, Elizabeth E.

doi:10.1016/j.aohep.2023.101142

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reduce appetite and body weight, improve insulin sensitivity, have antioxidant activity, promote an anti-inflammatory milieu, and improve mitochondrial health [58]. In a retrospective study of patients with type 2 diabetes, those taking GLP-1a had a lower risk of liver stiffness greater than 8 kPa compared to a historic cohort who were not taking GLP-1a medications (adjusted odds ratio 2.14) [59].…”

Section: Perioperative Risk Stratification By Assessment Of Liver Sti...mentioning

confidence: 99%

Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine

Suffredini,

Gao,

Dodd-o

2024

JCM

View full text Add to dashboard Cite

Ultrasound shear wave elastography (SWE) is a non-invasive, low risk technology allowing the assessment of tissue stiffness. Used clinically for nearly two decades to diagnose and stage liver fibrosis and cirrhosis, it has recently been appreciated for its ability to differentiate between more subtle forms of liver dysfunction. In this review, we will discuss the principle of ultrasound shear wave elastography, its traditional utilization in grading liver cirrhosis, as well as its evolving role in identifying more subtle degrees of liver injury. Finally, we will show how this capacity to distinguish nuanced changes may provide an opportunity for its use in perioperative risk stratification.

show abstract

Section: Perioperative Risk Stratification By Assessment Of Liver Sti...mentioning

confidence: 99%

Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine

Suffredini,

Gao,

Dodd-o

2024

JCM

View full text Add to dashboard Cite

show abstract

“…Multiple in vivo and in vitro investigations have shown that SGLT2i may be used as a treatment option for NAFLD. [13][14][15][16][17] Like other SGLT2i, empagliflozin has been the subject of many randomized controlled studies. [18][19][20] Despite this, there is a lack of research on the impacts and mechanisms of empagliflozin in obesity-related NAFLD.…”

Section: Introductionmentioning

confidence: 99%

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice

Niu,

Ren,

Chen

et al. 2023

DMSO

View full text Add to dashboard Cite

Purpose Among chronic liver diseases, non-alcoholic fatty liver disease (NAFLD) is one of the commonest. Although empagliflozin has several therapeutic uses in treating cardiovascular and renal disorders, its impacts and mechanisms on NAFLD are poorly understood. This research aimed to examine the metabolic regulatory mechanism through which empagliflozin protects against NAFLD. Methods Equal grouping of twenty-seven male C57BL/6J mice into those fed a normal diet (NCD), those fed a high-fat diet (HFD), and those fed an HFD with empagliflozin (Empa) was approached. HE, oil red O staining, and Masson staining were utilized for evaluating the pathological damage to the liver and the mice’s liver and body weights. Lipids, blood glucose, and inflammation index were compared across the three groups. Liquid chromatography/mass spectrometry (LC-MS) has been employed for identifying liver metabolomics. Results The findings suggested that empagliflozin mitigated the inflammatory and oxidative stress response associated with the buildup of lipids caused by HFD. Differentially expressed metabolites (DEMs) were identified by metabonomics analysis as present in both the HFD/NCD and Empa/HFD groups. These DEMs were primarily found in lipids and organic acids like lysophosphatidylcholine (lysoPC), lecithin (PC), triglyceride (TG), palmitic acid, and L-isoleucine. Among the enriched pathways that were shown to be important were those involved in the metabolism of histidine, arachidonic acid, the control of lipolysis in adipocytes, and insulin resistance. There was a strong correlation between inflammation and oxidative stress in most of the metabolites. The inflammation and oxidative stress unbalance were ameliorated by empagliflozin. Conclusion NAFLD mice model showed considerable improvement in metabolic abnormalities and liver protection after treatment with empagliflozin. The process may include the overexpression of L-isoleucine and the downregulation of lysoPC, PC, TG, and palmitic acid to reduce liver harm caused by lipotoxicity.

show abstract

Glucagon-Like Peptide-1 Receptor Agonists: Best Choice for Patients With Cirrhosis and Diabetes?

Li,

Wang

2024

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists

Cited by 4 publications

References 40 publications

Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine

Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice

Glucagon-Like Peptide-1 Receptor Agonists: Best Choice for Patients With Cirrhosis and Diabetes?

Contact Info

Product

Resources

About